Contents

Search

fluticasone/vilanterol (Breo Ellipta)

Indications: - combination inhaler therapy for treatment of - COPD [1]*, reduces risk of COPD exacerbations [5] - asthma in adults [2,6] * no improvement in mortality [4] * safe for patients with cardiovascular disease [4] Contraindications: - not FDA-approved to treat asthma in children or adolescents or to treat acute bronchospasm [2] Dosage: - once a day dry powder Mechanism of action: - combination of inhaled glucocorticoid (fluticasone) with long-acting beta-2 adrenergic receptor agonist (vilanterol)

General

LABA/LAMA combination

References

  1. Physician's First Watch, May 1, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org - FDA News Release: May 10, 2013 FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease
  2. GlaxoSmithKline News Release. April 30, 2015 FDA approves BREO ELLIPTA for the treatment of adults with asthma in the US. http://us.gsk.com/en-us/media/press-releases/2015/fda-approves-breo-ellipta-for-the-treatment-of-adults-with-asthma-in-the-us/
  3. Kerwin EM, Scott-Wilson C, Sanford L et al A randomised trial of fluticasone furoate/vilanterol (50/25 ug; 100/25 ug) on lung function in COPD. Respir Med. 2013 Apr;107(4):560-9 PMID: 23352226
  4. Vestbo J, Anderson JA, Brook RD et al Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016 Apr 30;387(10030):1817-26. PMID: 27203508 - Brusselle G. Vilanterol fluticasone and mortality in comorbid COPD GOLD B. Lancet. 2016 Apr 30;387(10030):1791-2. Epub 2016 Apr 28. PMID: 27203487
  5. Vestbo J, Leather D, Diar Bakerly N et al Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. N Engl J Med. Sept 4, 2016 PMID: 27593504 Free Article http://www.nejm.org/doi/full/10.1056/NEJMoa1608033
  6. Woodcock A, Vestbo J, Bakerly ND et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: An open-label, parallel group, randomised controlled trial. Lancet 2017 Sep 10; PMID: 28903864 - Gibson P. Effectiveness trials in asthma: Time to SaLSA? Lancet 2017 Sep 10 PMID: 28903863